Figure 1.

Pan‐cancer analysis of CDK12 alterations. (A): Frequency of CDK12 loss‐of‐function (LOF) alterations across multiple tumor types. Cancer types included are those with at least 100 sequenced samples and with ≥1 case with CDK12‐LOF alteration. Full details of cancer‐type prevalence are included in supplemental online Table 3. “Multiple” indicates samples with ≥2 concurrent CDK12 genomic alterations (GAs). (B): Relative fraction of cases with each class of CDK12 alteration. Cancer types with ≥50 CDK12 GA cases were individually assessed in this analysis. Short variant alterations were evaluated for zygosity. (C): Bi‐allelic fraction was determined for cases where mono‐allelic versus bi‐allelic status could be determined. Bi‐allelic alterations included copy number loss, mutation with wild‐type copy under loss of heterozygosity, or multiple detected alterations in a given case. Mono‐allelic mutations were those determined as heterozygous.

Abbreviations: CRC, colorectal cancer; CUP, cancer of unknown primary; GIST, gastrointestinal stromal tumor; NSCLC, non‐small cell lung cancer; SCC, squamous cell carcinoma.